ACE2 and COVID-19: Conversely, since the down-regulation of ACE2 subsequent to SARS-CoV-2 infection could attenuate the protective effects of ACE2, the continued usage of ACEi and ARBs with resultant increase in ACE2 expression may be beneficial in preventing excessive activation of RAAS that may ensue following COVID-19 [5, 8].